Gastric and Esophageal pH in Patients With Barrett's Esophagus Treated With Three Esomeprazole Dosages: A Randomized, Double-Blind, Crossover Trial

Spechler, Stuart J.; Sharma, Prateek; Traxler, Barry; Levine, Douglas; Falk, Gary W.
September 2006
American Journal of Gastroenterology;Sep2006, Vol. 101 Issue 9, p1964
Academic Journal
BACKGROUND: It has been suggested that patients with Barrett's esophagus (BE) are unusually resistant to the antisecretory effects of proton pump inhibitors (PPIs). OBJECTIVES: To compare intragastric and intraesophageal acidity in patients with BE receiving esomeprazole 40 mg three times daily (t.i.d.), esomeprazole 40 mg twice daily (b.i.d.), and esomeprazole 20 mg t.i.d. METHODS: In this randomized, double-blind, three-way crossover study, patients with long-segment BE received each of the three esomeprazole dosages for 5 days separated by 10–14-day washout periods. Intragastric and intraesophageal pHs were measured for 24 h on day 5. RESULTS: Among 31 patients with evaluable pH data, intragastric pH was >4.0 for 88.4%, 81.4%, and 80.4% of day 5 after treatment with esomeprazole 40 mg t.i.d., 40 mg b.i.d., and 20 mg t.i.d., respectively. Esomeprazole 40 mg t.i.d. was significantly more effective than the other dosages ( p < 0.01). Intraesophageal pH was <4.0 for mean values of <5% of the monitoring period with all the three dosing regimens, but esophageal pH remained <4.0 for >5% of the time in 16%, 23%, and 19% of patients receiving esomeprazole 40 mg t.i.d., 40 mg b.i.d., and 20 mg t.i.d., respectively. All dosages were well tolerated. CONCLUSIONS: All the three esomeprazole dosages significantly decreased intragastric acidity and reduced esophageal acid exposure to mean normal values in the total group of patients with BE. However, abnormal esophageal acid exposure continued in 16–23% of patients despite the significant decrease in gastric acidity. These results suggest that the apparent “PPI resistance” described in patients with BE may be caused by their profound reflux diathesis rather than by gastric resistance to the antisecretory effects of PPIs.


Related Articles

  • Intravenous Lansoprazole: In Erosive Oesophagitis. Dando, Toni M.; Plosker, Greg L. // Drugs;2004, Vol. 64 Issue 18, p2085 

    â–´ An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole. â–´ In healthy volunteers, oral and intravenous lansoprazole 30 mg/day were equivalent in suppressing...

  • Acid Inhibition in GERD–How Much is Enough? Achem, Sami R. // American Journal of Gastroenterology;Jun2004, Vol. 99 Issue 6, p997 

    Gastric acid plays a fundamental role in the development of mucosal injury and symptoms in gastro-esophageal reflux disease(GERD). In this issue of theJournal, Milkes et al report the inability of proton pump inhibitor (PPIs) therapy to“normalize” 24-hour intraesophageal pH...

  • BARRETT'S ESOPHAGUS: ACID SUPPRESSION, BUT NO REGRESSION. Bozymski, Eugene M.; Shaheen, Nicholas J. // American Journal of Gastroenterology;Apr1997, Vol. 92 Issue 4, p556 

    Discusses the results of a study on the treatment of patients with Barrett's esophagus with a proton pump inhibitor. Number of patients used in the study; Explanation on the efforts to understand the pathogenic and sustaining mechanism of Barrett's esophagus; Difficulty of quantifying changes...

  • Therapeutic approaches to reflux disease: newer approaches and strategies to columnar-lined esophagus. Spechler, Stuart Jon // Journal of Gastroenterology;2003 Supplement 15, Vol. 38, p20 

    Examines new therapeutic approaches to gastroesophageal reflux disease (GERD). Aim of antireflux therapy to eliminate the signs and symptoms reflux esophagitis and prevention of GERD complications such as peptic esophageal stricture and adenocarcinoma; Focus of modern medical antireflux therapy...

  • Proton Pump Inhibitors: Do Differences in Pharmacokinetics Translate into Differences in Clinical Outcomes? Kwong Ming Fock; Tiing Leong Ang; Lean Choo Bee; Jon Deon Lee, Edmund // Clinical Pharmacokinetics;2008, Vol. 47 Issue 1, p1 

    Acid-related disorders are common management problems in clinical practice. The key to effective management is successful suppression of gastric acid production. Proton pump inhibitors (PPIs) are the most potent acid suppressants available and are significantly more effective than histamine H2...

  • Pantoprazole Therapy in the Long-Term Management of Severe Acid Peptic Disease. Bardhan, Karna Dev; Cherian, Pradip; Bishop, Anne E.; Polak, Julia M.; Perry, Michael J.; Rowland, Anne; Thompson, Mary; Morris, Pamela; Schneider, Andreas; Fischer, Renata; Ng, W.; Lühmann, R.; McCaldin, Brian // American Journal of Gastroenterology;Jun2001, Vol. 96 Issue 6, p1767 

    OBJECTIVE: Pantoprazole is the third proton pump inhibitor to become available. When this study was started, there were few data on its long-term use. Our aim was to investigate this aspect and, because powerful inhibitors of acid secretion can cause hypergastrinemia and, in experimental...

  • Barrett's Esophagus: Symptoms, Diagnosis, and Treatment. Green, Erin E. // Clinical Excellence for Nurse Practitioners;Spring2005, Vol. 9 Issue 1, p7 

    Patients experiencing gastroesophageal reflux on a regular basis may be predisposed to Barrett's esophagus. Barrett's is thought to be a precursor to esophageal cancer. Endoscopy is utilized for both diagnosis and surveillance of this disease. The use of proton pump inhibitors and H2 blockers...

  • Effect of Proton Pump Inhibitor Therapy on Inflammatory Changes in the Gastric Cardia (Carditis). Shailender Singh; Ajay Bansal; Srinivas Puli; Sachin Wani; Sharad Mathur; Amit Rastogi // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2178 

    Abstract  The etiology of inflammation of the gastric cardia (carditis) is controversial, and gastroesophageal reflux disease (GERD) and H. pylori infection have been proposed as etiological factors. This study aimed to investigate the effect of acid suppression on histological...

  • Acid inhibitory medication and risk of gastric and oesophageal cancer. McColl, K.E. L. // Gut;Nov2006, Vol. 55 Issue 11, p1532 

    The article examines the effects of acid suppressive medications on the risk of gastric and malignancy of the esophagus. Adenocarcinoma of the gullet and stomach occurred more frequently in those patients taking antisecretory medicines. The drugs had threefold and twofold increased the risk of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics